Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Findings from the CONFIRM clinical trial presented at the 2012 San Antonio Breast Cancer Symposium in December showed that increasing the dose of fulvestrant (Faslodex) from 250 mg to 500 mg for women with estrogen receptor-positive metastatic breast cancer increased median overall survival by 4.1 months. Overall survival is the time a person lives from the start of treatment until death from any cause.
Women who waited more than 60 days after a late-stage breast cancer diagnosis were 85 percent more likely to die from the disease than women who began treatment sooner, a retrospective analysis of medical records showed. For this study, late-stage included any cancer that traveled to lymph nodes, regardless of cancer stage.
A follow-up assessment of data from the National Surgical Adjuvant Breast and Bowel Project B-31 (NSABP B-31) clinical trial showed that adding trastuzumab (Herceptin) to combination chemotherapy treatment raises the risk of heart problems, but they are not long-term.
A study of 12,500 women treated for HER2 positive breast cancer showed an association between the use of an anthracycline, trastuzumab (Herceptin) or other chemotherapy and the development of heart failure or cardiomyopathy, disease of the heart muscle. Through analysis of existing medical records, the results support findings of past clinical trials.
LONDON (Reuters) - British women with a family history of breast cancer could be offered two drugs to try to prevent the disease under draft guidelines published by the country's healthcare cost watchdog.
NEW YORK (Reuters Health) - Doctors relying on studies published in top journals for guidance about how to treat women with breast cancer may not be getting the most accurate information, according to a new analysis.
NEW YORK (Reuters Health) - Screening women for breast cancer costs the U.S. Medicare program $1 billion every year - about as much as it spends on treatment, according to a new study.
HONG KONG (Reuters) - The discovery that a protein that triggers milk production in women may also be responsible for making breast cancers aggressive could open up new opportunities for treatment of the most common and deadliest form of cancer among women.
A report issued by the U.S. Centers for Disease Control and Prevention shows that African-American women are diagnosed with breast cancer less often than white women but continue to experience higher death rates.
An analysis of data collected in the Surveillance, Epidemiology and End Results (SEER)-Medicare database between 2002 and 2007 shows that though newer, less invasive breast cancer staging procedures have become standard, African-American women were 12 percent less likely to have the less invasive surgery than their white peers.